Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ennatostat for anemia associated with myelofibrosis
ChiCTR2500102128Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of enarodustat in anemia of myelofibrosis, myelofibrosis (MF) and myeloproliferative disorder (MPD) (2 arms), sponsored by Fujian Medical University Union Hospital. Primary endpoints: Red lineage response rate and Proportion of subjects removed from transfusion dependence. Planned start May 2025; status: not yet recruiting.
02
Drugs
enarodustat
03
Conditions
anemia of myelofibrosismyelofibrosis (MF)myeloproliferative disorder (MPD)
Beyond the preview
Go deeper on ChiCTR2500102128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102128.